Lung Cancer
Targeted Therapy in NSCLC
Ahn M-J et al. Osimertinib for patients (pts) with leptomeningeal metastases (LM) associated with EGFRm advanced NSCLC: The AURA LM study. Proc ELCC 2019;Abstract 105O.
Barlesi F et al. Entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small cell lung cancer (NSCLC): Integrated analysis of ALKA-372-001, STARTRK-1 and STARTRK-2. Proc ELCC 2019;Abstract 109O.
Califano R et al. Brigatinib (BRG) versus crizotinib (CRZ) in the phase III ALTA-1L trial. Proc ELCC 2019;Abstract 106O.
Doebele R et al. Entrectinib in NTRK-fusion positive (NTRK-FP) non-small cell lung cancer (NSCLC): Integrated analysis of patients enrolled in three trials (STARTRK-2, STARTRK-1 and ALKA-372-001). Proc AACR 2019;Abstract CT131.
Drilon A et al. Registrational results of LIBRETTO-001: A phase 1/2 trial of LOXO-292 in patients with RET fusion-positive lung cancers. IASLC WCLC 2019;Abstract PL02.08.
Gainor JF et al. Clinical activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients (pts) with advanced RET-fusion+ non-small cell lung cancer (NSCLC). ASCO 2019;Abstract 9008.
Govindan R et al. Phase I study of AMG 510, a novel molecule targeting KRAS G12C mutant solid tumours. Proc ESMO 2019;Abstract 446PD.
Heymach J et al. A phase II trial of poziotinib in EGFR and HER2 exon 20 mutant non-small cell lung cancer (NSCLC). Proc WCLC 2018;Abstract OA02.06.
Jänne PA et al. Antitumor activity of TAK-788 in NSCLC with EGFR exon 20 insertions. ASCO 2019;Abstract 9007.
Jänne PA et al. Osimertinib plus platinum/pemetrexed in newly-diagnosed advanced EGFRm-positive NSCLC: The phase 3 FLAURA2 study. IASLC WCLC 2019;Abstract OA07.01.
Paik PK et al. Phase II study of tepotinib in NSCLC patients with METex14 mutations. ASCO 2019;Abstract 9005.
Paz-Ares L et al. Entrectinib in NTRK fusion-positive NSCLC: Integrated analysis of patients enrolled in STARTRK-2, STARTRK-1 and ALKA-372-001. Proc ELCC 2019;Abstract 1130.
Ramalingam SS et al. Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA): Final overall survival analysis. Proc ESMO 2019;Abstract LBA5_PR.
Shepherd F. Targeted therapy: The new frontier. Education Session. ASCO 2019. https://meetinglibrary.asco.org/record/168046/video.
Solomon BJ et al. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: Results from a global phase 2 study. Lancet Oncol 2018;19(12):1654-67. Abstract
Wolf J et al. Capmatinib (INC280) in METΔex14-mutated advanced non-small-cell lung cancer (NSCLC): Efficacy data from the phase II GEOMETRY mono-1 study. ASCO 2019;Abstract 9004.
Wolf J et al. Phase 3 ALUR study of alectinib in pretreated ALK+ NSCLC: Final efficacy, safety and targeted genomic sequencing analyses. IASLC WCLC 2019;Abstract OA02.07.
Immune Checkpoint Inhibitors (ICIs) in Patients with SCLC
Brahmer JR et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2018;36(17):1714-68. Abstract
Chung HC et al. Pembrolizumab after two or more lines of prior therapy in patients with advanced small-cell lung cancer (SCLC): Results from the KEYNOTE-028 and KEYNOTE-158 studies. Proc AACR 2019;Abstract CT073.
Horn L et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med 2018;379(23):2220-9. Abstract
Liu S et al. IMpower 133: Primary PFS, OS and safety in a PH1/3 study of 1L atezolizumab + carboplatin + etoposide in extensive-stage SCLC. Proc WCLC 2018;Abstract PL02.07.
Paz-Ares L et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): A randomized, controlled, open-label, phase 3 trial. Lancet 2019;[Epub ahead of print].Abstract
Paz-Ares L et al. PD-L1 expression, patterns of progression and patient-reported outcomes (PROs) with durvalumab plus platinum-etoposide in ES-SCLC: Results from CASPIAN. Proc ESMO 2019;Abstract LBA89.
Paz-Ares L et al. Overall survival with durvalumab plus platinum-etoposide in first-line extensive-stage SCLC: Results from the CASPIAN study. IASLC WCLC 2019;Abstract PL02.11.
Reck M et al. IMpower133: Updated overall survival (OS) analysis of first-line (1L) atezolizumab (atezo) + carboplatin + etoposide in extensive-stage SCLC (ES-SCLC). Proc ESMO 2019; Abstract 1736O.
ICIs in Locally Advanced NSCLC: Neoadjuvant Treatment
Antonia SJ et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med 2018;379(24):2342-50. Abstract
Cascone T et al. Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cell lung cancer (NSCLC): Clinical and correlative results from the NEOSTAR study. ASCO 2019;Abstract 8504.
Kwiatkowski DJ et al. Neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC): Interim analysis and biomarker data from a multicenter study (LCMC3). ASCO 2019;Abstract 8503.
Integration of ICIs into Therapy for Metastatic NSCLC
Mok TSK et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): A randomized, open-label, controlled, phase 3 trial. Lancet 2019;393(10183):1819-30. Abstract
Paz-Ares L et al. Pembrolizumab plus chemotherapy for squamous non-small cell lung cancer. N Engl J Med 2018;379(21):2040-51. Abstract
Peters S et al. Nivolumab (NIVO) + low-dose ipilimumab (IPI) vs platinum-doublet chemotherapy (chemo) as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (NSCLC): CheckMate 227 part 1 final analysis. Proc ESMO 2019;Abstract LBA4_PR.
Ready N et al. First-line nivolumab plus ipilimumab in advanced non-small cell lung cancer (CheckMate 568): Outcomes by programmed death ligand 1 and tumor mutational burden as biomarkers. J Clin Oncol 2019;37(12):992-1000. Abstract
Reck M et al. IMpower150: An exploratory analysis of efficacy outcomes in patients with EGFR mutations. Proc ELCC 2019;Abstract 104O.
Acute Leukemias
Acute Myeloid Leukemia
Cortes JE et al. Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: Phase 2 study results. Am J Hematol 2018;93(11):1301-10. Abstract
Dinardo CD et al. Mutant IDH1 inhibitor ivosidenib (IVO; AG-120) in combination with azacitidine (AZA) for newly diagnosed acute myeloid leukemia (ND AML). ASCO 2019;Abstract 7011.
DiNardo CD et al. Venetoclax combined with decitabine or azacitidine in treatment-näive, elderly patients with acute myeloid leukemia. Blood 2019;133(1):7-17. Abstract
Lancet JE et al. CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia. J Clin Oncol 2018;36(26):2684-92. Abstract
Levis MJ et al. Effect of gilteritinib on survival in patients with FLT3-mutated (FLT3mut+) relapsed/refractory (R/R) AML who have common AML co-mutations or a high FLT3-ITD allelic ratio. ASCO 2019;Abstract 7000.
Perl A et al. Gilteritinib significantly prolongs overall survival in patients with FLT3-mutated (FLT3mut+) relapsed/refractory (R/R) acute myeloid leukemia (AML): Results from the phase 3 ADMIRAL trial. EHA 2019;Abstract S876.
Pollyea DA et al. Enasidenib, an inhibitor of mutant-IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia. Leukemia 2019;33(11):2575-84. Abstract
Ritchie EK et al. Outcomes with CPX-351 versus 7+3 by baseline bone marrow (BM) blast percentage in older adults with newly diagnosed high-risk/secondary acute myeloid leukemia (sAML). ASCO 2019;Abstract 7042.
Roboz GJ et al. Design of the randomized, phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemia. Future Oncol 2016;12(3):293-302. Abstract
Roboz GJ et al. Ivosidenib (IVO; AG-120) in IDH1-mutant newly-diagnosed acute myeloid leukemia (ND AML): Updated results from a phase 1 study. ASCO 2019;Abstract 7028.
Stein EM et al. Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib. Blood 2019;133(7):676-87. Abstract
Wei AH et al. Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: Results from a phase Ib/II study. J Clin Oncol 2019;37(15):1277-84. Abstract
Acute Lymphoblastic Leukemia
Goekbuget N et al. Blinatumomab for minimal residual disease (MRD) in adults with B-cell precursor acute lymphoblastic leukemia (BCPALL): Median overall survival (OS) not reached at 5 years for complete MRD responders. EHA 2019;Abstract S1619.
Grupp S et al. Tisagenlecleucel appears effective and safe in pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia with high-risk cytogenetic abnormalities. EHA 2019;Abstract S1618.
Shah BD et al. End of phase I results of ZUMA-3, a phase 1/2 study of KTE-X19, anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, in adult patients (pts) with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL). ASCO 2019;Abstract 7006.
Shah BD et al. KTE-X19, an anti-CD19 chimeric antigen receptor T-cell therapy, in adult patients with relapsed/refractory acute lymphoblastic leukemia: End of phase 1 results of ZUMA-3. EHA 2019;Abstract PS945.
Stock W et al. A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: Results of CALGB 10403. Blood 2019;133(14):1548-59. Abstract
Gastrointestinal Cancers
Colorectal Cancer
Argiles G et al. Results of REARRANGE trial: A randomized phase 2 study comparing different dosing approaches for regorafenib (REG) during the first cycle of treatment in patients (pts) with metastatic colorectal cancer (mCRC). ESMO World Congress GI 2019;Abstract O-026.
Bekaii-Saab TS et al. Regorafenib dose-optimization in patients with refractory metastatic colorectal cancer (ReDOS): A randomized, multicenter, open-label, phase 2 study. Lancet Oncol 2019;20(8):1070-82. Abstract
Fukuoka S et al. Regorafenib plus nivolumab in patients with advanced gastric (GC) or colorectal cancer (CRC): An open-label, dose-finding, and dose-expansion phase 1b trial (REGONIVO, EPOC1603). ASCO 2019;Abstract 2522.
Jonker DJ et al. Napabucasin versus placebo in refractory advanced colorectal cancer: A randomized phase 3 trial. Lancet Gastroenterol Hepatol 2018;3(4):263-70. Abstract
Kopetz S et al. BEACON CRC: A randomized, 3-arm, phase 3 study of encorafenib and cetuximab with or without binimetinib vs choice of either irinotecan or FOLFIRI plus cetuximab in BRAF V600E–mutant metastatic colorectal cancer. ESMO World Congress GI 2019;Abstract LBA-006.
Meric-Bernstam F et al. Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): An updated report from a multicenter, open-label, phase 2a, multiple basket study. Lancet Oncol 2019;20(4):518-30. Abstract
Overman MJ et al. Nivolumab (NIVO) + low-dose ipilimumab (IPI) in previously treated patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Long-term follow-up. Gastrointestinal Cancers Symposium 2019;Abstract 635.
Pfeiffer P et al. Bevacizumab improves efficacy of trifluridine/tipiracil (TAS-102) in patients with chemorefractory metastatic colorectal cancer: A Danish randomized trial. ESMO World Congress GI 2019;Abstract O-014.
Shitara K et al. REVERCE: A randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for previously treated metastatic colorectal cancer patients. Ann Oncol 2019;30(2):259-65. Abstract
Strickler JH et al. Trastuzumab and tucatinib for the treatment of HER2 amplified metastatic colorectal cancer (mCRC): Initial results from the MOUNTAINEER trial. Proc ESMO 2019;Abstract 527PD.
Willis J et al. Validation of microsatellite instability detection using a comprehensive plasma-based genotyping panel. Clin Cancer Res 2019;[Epub ahead of print]. Abstract
Pancreatic Cancer
Golan T et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med 2019;381(4):317-27. Abstract
Hubner RA et al. Quality of life in metastatic pancreatic cancer patients receiving liposomal irinotecan plus 5-fluorouracil and leucovorin. Eur J Cancer 2019;106:24-33. Abstract
Kindler HL et al. Olaparib as maintenance treatment following first-line platinum-based chemotherapy (PBC) in patients (pts) with a germline BRCA mutation and metastatic pancreatic cancer (mPC): Phase III POLO trial. ASCO 2019;Abstract LBA4.
Reni M et al. An international, randomized, open-label, phase III trial of adjuvant nab-paclitaxel plus gemcitabine vs gemcitabine alone for surgically resected pancreatic adenocarcinoma (APACT): Primary analysis and quality of life outcomes. ESMO World Congress GI 2019;Abstract O-001.
Tempero MA et al. APACT: Phase III, multicenter, international, open-label, randomized trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) for surgically resected pancreatic adenocarcinoma. ASCO 2019;Abstract 4000.
Wang-Gillam A et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): A global, randomized, open-label, phase 3 trial. Lancet 2016;387(10018):545-57. Abstract
Wang-Gillam A et al. NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors. Eur J Cancer 2019;108:78-87. Abstract
Hepatocellular Carcinoma
Abou-Alfa GK et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med 2018;379(1):54-63. Abstract
Abou-Alfa GK et al. ClarIDHy: A global, phase III, randomized, double-blind study of ivosidenib (IVO) vs placebo in patients with advanced cholangiocarcinoma (CC) with an isocitrate dehydrogenase 1 (IDH1) mutation. Proc ESMO 2019;Abstract LBA10.
Finn RS et al. Results of KEYNOTE-240: Phase 3 study of pembrolizumab (pembro) vs best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC). ASCO 2019;Abstract 4004.
Ikeda M et al. A Phase Ib trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC): Updated results. Proc AACR 2019;Abstract CT061.
Kudo M et al. Analysis of survival and objective response (OR) in patients with hepatocellular carcinoma in a phase III study of lenvatinib (REFLECT). Gastrointestinal Cancers Symposium 2019;Abstract 186.
Kudo M et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomized phase 3 non-inferiority trial. Lancet 2018;391(10126):1163-73. Abstract
Lee M et al. Randomized efficacy and safety results for atezolizumab (Atezo) + bevacizumab (Bev) in patients (pts) with previously untreated, unresectable hepatocellular carcinoma (HCC). Proc ESMO 2019;Abstract LBA39.
Yau T et al. CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC). Proc ESMO 2019;Abstract LBA38_PR.
Zhu AX et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): A randomized, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2019;20(2):282-96. Abstract
Zhu AX et al. REACH-2: A randomized, double-blind, placebo-controlled phase 3 study of ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP) following first-line sorafenib. ASCO 2018;Abstract 4003.
Gastroesophageal Cancer
Cho BC et al. Nivolumab versus chemotherapy in advanced esophageal squamous cell carcinoma (ESCC): The phase III ATTRACTION-3 study. Proc ESMO 2019;Abstract LBA11.
Kojima T et al. Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: Phase III KEYNOTE-181 study. Gastrointestinal Cancers Symposium 2019;Abstract 2.
Metges J et al. The phase 3 KEYNOTE-181 study: Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer. ESMO World Congress GI 2019;Abstract O-012.
Shitara K et al. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): A randomized, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2018;19(11):1437-48. Abstract
Tabernero J et al. Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The phase III KEYNOTE-062 study. ASCO 2019;Abstract LBA4007.
Tabernero J et al. Pembrolizumab with or without chemotherapy versus chemotherapy for first-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The phase 3 KEYNOTE-062 study. ESMO World Congress GI 2019;Abstract LBA-002.
Genitourinary Cancers
Prostate Cancer
Abida W et al. Preliminary results from TRITON2: A phase II study of rucaparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination repair (HRR) gene alterations. Proc ESMO 2018;Abstract 793PD.
Armstrong AJ et al. ARCHES: A randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J Clin Oncol 2019;37(32):2974-86. Abstract
Armstrong AJ et al. Prospective multicenter validation of androgen receptor splice variant 7 and hormone therapy resistance in high-risk castration-resistant prostate cancer: The PROPHECY study. J Clin Oncol 2019;37(13):1120-9. Abstract
Chi KN et al. Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med 2019;381(1):13-24. Abstract
De Giorgi U et al. A phase III, randomized, double-blind, placebo-controlled study of enzalutamide in men with nonmetastatic castration-resistant prostate cancer: Post-hoc analysis of PROSPER by prior therapy. Genitourinary Cancers Symposium 2019;Abstract 185.
de Wit R et al. CARD: Randomized, open-label study of cabazitaxel (CBZ) vs abiraterone (ABI) or enzalutamide (ENZ) in metastatic castration-resistant prostate cancer (mCRPC). Proc ESMO 2019;Abstract LBA13.
Fizazi K et al. Darolutamide in nonmetastatic, castration-resistant prostate cancer. N Engl J Med 2019;380(13):1235-46. Abstract
Hussain M et al. PROfound: Phase III study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations. Proc ESMO 2019;Abstract LBA12_PR.
Mateo J et al. TOPARP-B: A phase II randomized trial of the poly(ADP)-ribose polymerase (PARP) inhibitor olaparib for metastatic castration resistant prostate cancers (mCRPC) with DNA damage repair (DDR) alterations. ASCO 2019;Abstract 5005.
Small EJ et al. Updated analysis of progression-free survival with first subsequent therapy (PFS2) and safety in the SPARTAN study of apalutamide (APA) in patients (pts) with high-risk nonmetastatic castration-resistant prostate cancer (nmCRPC). Genitourinary Cancers Symposium 2019;Abstract 144.
Smith M et al. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): A randomized, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2019;20(3):408-19. Abstract
Smith MR et al. Pre-specified interim analysis of GALAHAD: A phase II study of niraparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD). Proc ESMO 2019;Abstract LBA50.
Sweeney C et al. Overall survival (OS) results of a phase III randomized trial of standard-of-care therapy with or without enzalutamide for metastatic hormone-sensitive prostate cancer (mHSPC): ENZAMET (ANZUP 1304), an ANZUP-led international cooperative group trial. ASCO 2019;Abstract LBA2.
Tombal BF et al. Decreased fracture rate by mandating bone-protecting agents in the EORTC 1333/PEACE III trial comparing enzalutamide and Ra223 versus enzalutamide alone: An interim safety analysis. ASCO 2019;Abstract 5007.
Renal Cell Carcinoma
Emamekhoo H et al. Safety and efficacy of nivolumab plus ipilimumab (NIVO + IPI) in patients with advanced renal cell carcinoma (aRCC) with brain metastases: Interim analysis of CheckMate 920. ASCO 2019;Abstract 4517.
Motzer RJ et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 2019;380(12):1103-15. Abstract
Rini BI et al. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): A multicenter, open-label, phase 3, randomized controlled trial. Lancet 2019;393(10189):2404-15. Abstract
Rini BI et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal cell carcinoma. N Engl J Med 2019;380(12):1116-27. Abstract
Tannir NM et al. Thirty-month follow-up of the phase III CheckMate 214 trial of first-line nivolumab + ipilimumab (N + I) or sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC). Genitourinary Cancers Symposium 2019;Abstract 547.
Urothelial Bladder Cancer
Grande E et al. IMvigor130: Efficacy and safety from a phase III study of atezolizumab (atezo) as monotherapy or combined with platinum-based chemotherapy (PBC) vs placebo + PBC in previously untreated locally advanced or metastatic urothelial carcinoma (mUC). Proc ESMO 2019;Abstract LBA14_PR.
Hoimes CJ et al. EV-103: Initial results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma. Proc ESMO 2019;Abstract 901O.
Loriot Y et al. Erdafitinib in locally advanced or metastatic urothelial carcinoma. N Engl J Med 2019;381(4):338-48. Abstract
Petrylak DP et al. EV-301: Phase III study to evaluate enfortumab vedotin (EV) versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial cancer (la/mUC). Genitourinary Cancers Symposium 2019;Abstract TPS497.
Rosenberg JE et al. Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1/programmed death ligand 1 therapy. J Clin Oncol 2019;37(29):2592-600. Abstract
Suzman DL et al. FDA approval summary: Atezolizumab or pembrolizumab for the treatment of patients with advanced urothelial carcinoma ineligible for cisplatin-containing chemotherapy. Oncologist 2019;24(4):563-9. Abstract
Lymphomas and Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
Fischer K et al. Effect of fixed-duration venetoclax plus obinutuzumab (VenG) on progression-free survival (PFS), and rates and duration of minimal residual disease negativity (MRD–) in previously untreated patients (pts) with chronic lymphocytic leukemia (CLL) and comorbidities. ASCO 2019;Abstract 7502.
Fischer K et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med 2019;380(23):2225-36. Abstract
Flinn IW et al. The phase 3 DUO trial: Duvelisib vs ofatumumab in relapsed and refractory CLL/SLL. Blood 2018;132(23):2446-55. Abstract
Ghia P et al. ASCEND phase 3 study of acalabrutinib vs investigator’s choice of rituximab plus idelalisib (IdR) or bendamustine (BR) in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). EHA 2019;Abstract LB2606.
Jain N et al. Ibrutinib and venetoclax for first-line treatment of CLL. N Engl J Med 2019;380(22):2095-103. Abstract
Kater AP et al. Fixed duration of venetoclax-rituximab in relapsed/refractory (R/R) chronic lymphocytic leukemia eradicates minimal residual disease and prolongs survival: Post-treatment follow-up of the MURANO phase III study. J Clin Oncol 2019;37(4):269-77. Abstract
Moreno C et al. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukemia (iLLUMINATE): A multicenter, randomized, open-label, phase 3 trial. Lancet Oncol 2019;20(1):43-56. Abstract
Seymour JF et al. MURANO trial establishes feasibility of time-limited venetoclax-rituximab (VenR) combination therapy in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). Proc ASH 2018;Abstract 184.
Shanafelt TD et al. A randomized phase III study of ibrutinib (PCI-32765)-based therapy vs standard fludarabine, cyclophosphamide, and rituximab (FCR) chemoimmunotherapy in untreated younger patients with chronic lymphocytic leukemia (CLL): A trial of the ECOG-ACRIN Cancer Research Group (E1912). Proc ASH 2018;Abstract LBA-4.
Woyach JA et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med 2018;379(26):2517-28. Abstract
Hodgkin Lymphoma/T-Cell Lymphoma
Domingo-Domènech E et al. Nivolumab plus doxorubicin, vinblastine and dacarbazine for newly diagnosed advanced-stage classical Hodgkin lymphoma: 2-year extended follow-up from cohort D of the phase 2 CHECKMATE 205 study. EHA 2019;Abstract S821.
Gallamini A et al. Frontline brentuximab vedotin with chemotherapy for stage 3/4 classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study. EHA 2019;Abstract S820.
Horwitz S et al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): A global, double-blind, randomized, phase 3 trial. Lancet 2019;393(10168):229-40. Abstract
Diffuse Large B-Cell Lymphoma
Abramson JS et al. Lisocabtagene maraleucel (liso-cel) treatment of patients (pts) with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL) and secondary CNS lymphoma: Initial results from TRANSCEND NHL 001. ASCO 2019;Abstract 7515.
Locke FL et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): A single-arm, multicenter, phase 1-2 trial. Lancet Oncol 2019;20(1):31-42. Abstract
Nastoupil LJ et al. Axicabtagene ciloleucel (Axi-cel) CD19 chimeric antigen receptor (CAR T-cell therapy for relapsed/refractory large B-cell lymphoma: Real Word Experience. Proc ASH 2018;Abstract 91.
Schuster SJ et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med 2019;380(1):45-56. Abstract
Sehn LH et al. Polatuzumab vedotin (pola) plus bendamustine (B) with rituximab (R) or obinutuzumab (G) in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Updated results of a phase (Ph) Ib/II study. Proc ASH 2018;Abstract 1683.
Sehn LH et al. Randomized phase 2 trial of polatuzumab vedotin (pola) with bendamustine and rituximab (BR) in relapsed/refractory (r/r) FL and DLBCL. ASCO 2018;Abstract 7507.
Tilly H et al. Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: An open-label, non-randomized, phase 1b-2 study. Lancet Oncol 2019;20(7):998-1010. Abstract
Westin J et al. Smart start: Final results of rituximab, lenalidomide, and ibrutinib lead in prior to combination with chemotherapy for patients with newly diagnosed diffuse large B-cell lymphoma. ASCO 2019;Abstract 7508.
Follicular Lymphoma
Awan F et al. Treatment emergent adverse events vary with different PI3K inhibitors. EHA 2019;Abstract PF378.
Flinn IW et al. DYNAMO: A Phase II study of duvelisib (IPI-145) in patients with refractory indolent non-Hodgkin lymphoma. J Clin Oncol 2019;37(11):912-22. Abstract
Leonard JP et al. AUGMENT: A phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma. J Clin Oncol 2019;37(14):1188-99. Abstract
Leppä S et al. Long-term follow-up of patients (pts) with relapsed or refractory (r/r) follicular lymphoma (FL) treated with copanlisib. ASCO 2019;Abstract 7553.
Morschhauser F et al. Rituximab plus lenalidomide in advanced untreated follicular lymphoma. N Engl J Med 2018;379(10):934-47. Abstract
Townsend W et al. Obinutuzumab-based immunochemotherapy prolongs progression-free survival and time to next anti-lymphoma treatment in patients with previously untreated follicular lymphoma: Four-year results from the phase III GALLIUM study. Proc ASH2018;Abstract 1597.
Mantle Cell Lymphoma
Davids MS et al. Revised dose ramp-up to mitigate the risk of tumor lysis syndrome when initiating venetoclax in patients with mantle cell lymphoma. J Clin Oncol 2018;[Epub ahead of print]. Abstract
Eyre T et al. Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma post-BTK inhibition therapy. EHA 2018;Abstract S855.
Ruan J et al. Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma. Blood 2018;132(19):2016-25. Abstract
Wang M et al. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): A single-arm, multicenter, phase 2 trial. Lancet 2018;391(10121):659-67. Abstract
Wang M et al. Long-term follow-up of acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma. Proc ASH 2018;Abstract 2876.
Gynecologic Cancers
Ovarian Cancer
Coleman RL et al. VELIA/GOG-3005: Integration of veliparib (V) with front-line chemotherapy and maintenance in women with high-grade serous carcinoma of ovarian, fallopian tube, or primary peritoneal origin. ESMO 2019;Abstract LBA3.
Essel KG et al. PARPi after PARPi in epithelial ovarian cancer. SGO 2019;Abstract 7.
González-Martín A et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 2019;[Epub ahead of print]. Abstract
González-Martín A et al. Niraparib therapy in patients with newly diagnosed advanced ovarian cancer. ESMO 2019;Abstract LBA1.
Konstantinopoulos PA et al. Single-arm phases 1 and 2 trial of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma. JAMA Oncol 2019;[Epub ahead of print]. Abstract
Monk BJ et al. A prospective evaluation of tolerability of niraparib dosing based upon baseline body weight and platelet count: Blinded pooled interim safety data from the ENGOT-OV26/PRIMA study. SGO 2019;Abstract 3.
Moore KN et al. Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): A multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol 2019;20(5):636-48. Abstract
Moore K et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 2018;379(26):2495-505. Abstract
Moore KN et al. SOLO1 and SOLO2: Randomized phase III trials of olaparib in patients (pts) with ovarian cancer and a BRCA1/2 mutation (BRCAm). ASCO 2014;Abstract TPS5616.
Penson RT et al. Olaparib monotherapy versus (vs) chemotherapy for germline BRCA-mutated (gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): Phase III SOLO3 trial. ASCO 2019;Abstract 5506.
Ray-Coquard IL et al. Phase III PAOLA-1/ENGOT-ov25 trial: Maintenance olaparib with bevacizumab (bev) as maintenance therapy in patients (pts) with newly diagnosed, advanced ovarian cancer OC) treated with platinum-based chemotherapy (PCh) plus bev. ESMO 2019;Abstract LBA2.
Vanderstichele A et al. Randomized phase II CLIO study on olaparib monotherapy versus chemotherapy in platinum-resistant ovarian cancer. ASCO 2019;Abstract 5507.
Endometrial Cancer
Antill YC et al. Activity of durvalumab in advanced endometrial cancer (AEC) according to mismatch repair (MMR) status: The phase II PHAEDRA trial (ANZGOG1601). ASCO 2019;Abstract 5501.
Konstantinopoulos PA et al. Phase II study of avelumab in patients with mismatch repair deficient and mismatch repair proficient recurrent/persistent endometrial cancer. J Clin Oncol 2019;37(30):2786-94. Abstract
Makker V et al. Lenvatinib (LEN) and pembrolizumab (PEMBRO) in advanced endometrial cancer (EC). ESMO 2019;Abstract 994O.
Makker V et al. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: An interim analysis of a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol 2019;20(5):711-8. Abstract
Cervical Cancer
Chung HC et al. Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: Results from the phase II KEYNOTE-158 study. J Clin Oncol 2019;37(17):1470-8. Abstract
Breast Cancer
Localized and Metastatic HER2-Positive Breast Cancer
Borges VF et al. Tucatinib combined with ado-trastuzumab emtansine in advanced ERBB2/HER2-positive metastatic breast cancer: A phase 1b clinical trial. JAMA Oncol 2018;4(9):1214-20. Abstract
Geyer CE Jr et al. Phase III study of trastuzumab emtansine (T-DM1) vs trastuzumab as adjuvant therapy in patients with HER2-positive early breast cancer with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy including trastuzumab: Primary results from KATHERINE. San Antonio Breast Cancer Symposium 2018;Abstract GS1-10.
Hamilton E et al. Efficacy results of a phase 1b study of ONT-380, an oral HER2-specific inhibitor, in combination with capecitabine (C) and trastuzumab (T) in HER2+ metastatic breast cancer (MBC), including patients (pts) with brain metastases (mets). San Antonio Breast Cancer Symposium 2016;Abstract P4-21-01.
Modi S et al. A phase III, multicenter, randomized, open label trial of [fam-] trastuzumab deruxtecan (DS-8201a) versus investigator’s choice in HER2-low breast cancer. ASCO 2019;Abstract TPS1102.
Modi S et al. Trastuzumab deruxtecan (DS-8201a) in subjects with HER2-low expressing breast cancer: Updated results of a large phase 1 study. San Antonio Breast Cancer Symposium 2018;Abstract P6-17-02.
Murthy R et al. Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: A non-randomised, open-label, phase 1b study. Lancet Oncol 2018;19(7):880-8. Abstract
Rugo HS et al. SOPHIA primary analysis: A phase 3 (P3) study of margetuximab (M) + chemotherapy (C) versus trastuzumab (T) + C in patients (pts) with HER2+ metastatic (met) breast cancer (MBC) after prior anti-HER2 therapies (Tx). ASCO 2019;Abstract 1000.
Saura C et al. Neratinib + capecitabine versus lapatinib + capecitabine in patients with HER2+ metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: Findings from the multinational, randomized, phase III NALA trial. ASCO 2019;Abstract 1002.
Tamura K et al. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: A dose-expansion, phase 1 study. Lancet Oncol 2019;20(6):816-26. Abstract
von Minckwitz G et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med 2019;380(7):617-28. Abstract
Immunotherapy in Metastatic Triple-Negative Breast Cancer
Schmid P et al. IMpassion130: Updated overall survival (OS) from a global, randomized, double-blind, placebo-controlled, Phase III study of atezolizumab (atezo) + nab-paclitaxel (nP) in previously untreated locally advanced or metastatic triple-negative breast cancer (mTNBC). ASCO 2019;Abstract 1003.
Schmid P et al. KEYNOTE-522: Phase 3 study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (pbo) + chemo as neoadjuvant treatment, followed by pembro vs pbo as adjuvant treatment for early triple-negative breast cancer (TNBC). ESMO 2019;Abstract LBA8.
Schmid P et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med 2018;379(22):2108-21. Abstract
Schmid P et al. IMpassion130: Results from a global, randomised, double-blind, phase 3 study of atezolizumab (atezo) + nab-paclitaxel (nab-P) vs placebo + nab-P in treatment-naive, locally advanced or metastatic triple-negative breast cancer (mTNBC). ESMO 2018;Abstract LBA1_PR.
Schmid P et al. KEYNOTE-522: Phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo + chemo as neoadjuvant therapy followed by pembro vs placebo as adjuvant therapy for triple-negative breast cancer (TNBC). ASCO 2018;Abstract TPS602.
Schmid P et al. KEYNOTE-522: Phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo + chemo as neoadjuvant followed by pembro vs placebo as adjuvant therapy for triple-negative breast cancer (TNBC). ESMO 2017;Abstract 233TiP.
Schneeweiss A et al. IMpassion130: Expanded safety analysis from a P3 study of atezolizumab (A) + nab-paclitaxel (nP) in patients (pts) with treatment (tx)-naïve, locally advanced or metastatic triple-negative breast cancer (mTNBC). ASCO 2019;Abstract 1068.
Genomic Assays in Localized Breast Cancer
Sparano JA et al. Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer. N Engl J Med 2019;380(25):2395-405. Abstract
ER-Positive Metastatic Breast Cancer
André F et al. Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N Engl J Med 2019;380(20):1929-40. Abstract
André F et al. Alpelisib (ALP) + fulvestrant (FUL) for advanced breast cancer (ABC): Results of the phase 3 SOLAR-1 trial. ESMO 2018;Abstract LBA3_PR.
Im SA et al. Overall survival with ribociclib plus endocrine therapy in breast cancer. N Engl J Med 2019;381(4):307-16. Abstract
Park YH et al. A randomized phase II study of palbociclib plus exemestane with GNRH agonist versus capecitabine in premenopausal women with hormone receptor-positive metastatic breast cancer (KCSG-BR 15-10, NCT02592746). ASCO 2019;Abstract 1007.
Slamon DJ et al. Overall survival (OS) results of the phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor 2-negative (HER2−) advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB). ESMO 2019;Abstract LBA7.
Sledge GW et al. MONARCH 2: Overall survival of abemaciclib plus fulvestrant in patients with HR+, HER2- advanced breast cancer. ESMO 2019;Abstract LBA6.
Tolaney SM et al. monarcHER: A randomized Phase 2 study of abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with HR+, HER2+ advanced breast cancer (ABC). ESMO 2019;Abstract LBA23.
PARP Inhibitors
Diéras VC et al. Phase 3 study of veliparib with carboplatin and paclitaxel in HER2-negative advanced/metastatic gBRCA-associated breast cancer. ESMO 2019;Abstract LBA9.
Robson ME et al. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol 2019;30(4):558-66. Abstract